Endpoints News has recognized Holly Kordasiewicz, Ph.D., SVP, Neurology, in its 2025 Women in Biopharma R&D special report. The annual report highlights and honors women leaders in the biopharma industry who are blazing a trail and pushing gender diversity forward.
Dr. Kordasiewicz’s recognition reflects her lasting impact at Ionis, where she has helped transition 15 medicines from research into development, advancing the company’s mission to deliver life-changing therapies for patients with serious diseases.
An expert in neurology drug development, Dr. Kordasiewicz played an integral role in the discovery and development of Ionis’ medicine for a genetic form of amyotrophic lateral sclerosis (ALS) and contributed to the advancement of the IONIS-MAPTRX program, targeting the tau protein gene, a hallmark of Alzheimer’s disease.
Starting in January, Dr. Kordasiewicz will assuming the role of Chief Development Officer, overseeing the company’s entire portfolio.
Since its inception, the Women in Biopharma R&D feature has recognized more than 120 women whose work has redefined R&D — from pioneering breakthroughs in gene editing to advancing therapies for rare diseases. Dr. Kordasiewicz’s inclusion underscores not only her scientific accomplishments but also her commitment to mentoring the next generation of scientists and leaders in biopharma.
Read the full feature on Endpoints News.